Orca Bio

Headquartered in Menlo Park, California, Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. Their manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling them to create proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. Established in 2016, their therapeutic platform delivers high-precision allogeneic cell therapies by building each dose cell-by-cell from another person’s blood. Each therapy is constructed by formulating a proprietary mixture of cells uniquely suited for the patient. Their two novel cellular product candidates are now being tested in large multi-center studies, in patients with blood cancers. The products are to be used instead of a conventional bone marrow transplant. Their therapies are enabled by their proprietary manufacturing platform, which allows them to sort donor blood with single-cell precision at a high throughput. Their manufacturing platform has already successfully delivered high-precision cellular products across the continental USA with an unprecedented turn-around-time. As the demand for highly controlled and precisely defined cellular products continues to grow, Orca Bio is in prime position to meet that demand.